Skip to content
CancerIndex

Publication

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

Authors not recorded

BMC Cancer2012PMID 22439647PMC3361487stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

Curated evidence

Evidence citing this paper (4)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
22439647
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
KIT Exon 9 Mutation1
SunitinibGastrointestinal Stromal TumorPredictiveBSupports Sensitivity Response3accepted
EID1223

Primary tumor genotyping of 89 patients with metastatic GIST given 2nd-line sunitinib treatment after prior imatinib therapy failure, revealed an improved response to sunitinib in patients with KIT ex… (full text at CIViC)

PMID 22439647 · Rutkowski et al., 2012 · Open in CIViC

civic
KIT P551_E554delPMYE1
SunitinibGastrointestinal Stromal TumorPredictiveBSupports Resistance—submitted
EID4454

In a prospective study of 137 gastrointestinal stromal tumor patients who failed imatinib treatment, tumors with KIT exon 11 mutations (52/89) treated with sunitinib were associated with shorter prog… (full text at CIViC)

PMID 22439647 · Rutkowski et al., 2012 · Open in CIViC

civic
KIT S501_A502INSAY1
SunitinibGastrointestinal Stromal TumorPredictiveBSupports Sensitivity Response—submitted
EID4501

In a prospective study of 137 gastrointestinal stromal tumor patients who failed imatinib treatment, patients with KIT exon 9 mutations (15/89) treated with sunitinib were associated with improved pr… (full text at CIViC)

PMID 22439647 · Rutkowski et al., 2012 · Open in CIViC

civic
PDGFRA D842V1
SunitinibGastrointestinal Stromal TumorPredictiveBSupports Resistance3submitted
EID4058

In a prospective study of 137 gastrointestinal stromal tumor patients who failed imatinib treatment, patients with PDGFRA mutation (12/89; 11/12 tumors genotyped as D842V) treated with sunitinib were… (full text at CIViC)

PMID 22439647 · Rutkowski et al., 2012 · Open in CIViC

civic